Mimetogen Pharmaceuticals has announced the positive data from a Phase II clinical trial of MIM-D3 for the treatment of dry eye.

The 28-day Phase II study included 150 patients and demonstrated improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

Mimetogen president and CEO Garth Cumberlidge said the preliminary results are promising for the use of the drug as a treatment of dry eye.

The study used a controlled adverse environment chamber to measure the ability of patients with dry eye to withstand a stressful drying environment and measure the severity of their symptoms.